Madrigal Competitors
| MDGL Stock | USD 487.78 0.48 0.1% |
Madrigal Pharmaceuticals vs Baxter International Correlation
Very good diversification
The correlation between Madrigal Pharmaceuticals and BAX is -0.33 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and BAX in the same portfolio, assuming nothing else is changed.
Moving against Madrigal Stock
The value of Return On Tangible Assets is estimated to slide to -0.54. The value of Return On Capital Employed is expected to slide to -0.69. At this time, Madrigal Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year.Madrigal Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Madrigal Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Madrigal and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Madrigal Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Madrigal Stock performing well and Madrigal Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Madrigal Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RNA | 0.17 | 0.05 | (0.15) | 1.02 | 0.00 | 0.38 | 1.75 | |||
| JAZZ | 1.71 | 0.36 | 0.11 | (0.58) | 1.65 | 3.66 | 25.96 | |||
| MRNA | 3.34 | 0.79 | 0.21 | 0.48 | 3.49 | 9.21 | 23.11 | |||
| CAI | 2.49 | (0.42) | 0.00 | (7.05) | 0.00 | 4.14 | 19.89 | |||
| RYTM | 2.40 | (0.05) | (0.02) | 0.03 | 2.88 | 4.76 | 18.69 | |||
| ABVX | 3.22 | 0.38 | 0.08 | 4.95 | 3.43 | 6.94 | 29.38 | |||
| TECH | 1.79 | 0.00 | 0.02 | 0.09 | 1.75 | 3.76 | 10.34 | |||
| EXEL | 1.63 | 0.16 | 0.08 | 0.28 | 1.67 | 4.06 | 11.45 | |||
| BMRN | 1.58 | 0.11 | 0.05 | 0.26 | 1.46 | 3.15 | 22.06 | |||
| BAX | 1.52 | 0.22 | 0.11 | 0.32 | 1.47 | 3.50 | 9.48 |
Cross Equities Net Income Analysis
Compare Madrigal Pharmaceuticals and related stocks such as Avidity Biosciences, Jazz Pharmaceuticals PLC, and Moderna Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| JAZZ | (24.8 M) | 125 M | 288.6 M | 216.3 M | 58.4 M | 329.5 M | 396.8 M | 487.8 M | 447.1 M | 523.4 M | 238.6 M | (329 M) | (224.1 M) | 414.8 M | 560.1 M | 644.1 M | 676.3 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| CAI | (2.6 M) | 50.2 M | 63.5 M | 63.9 M | 60.3 M | 26.8 M | 6 M | 72.1 M | 78.6 M | 31 M | 27.7 M | (320.8 M) | (320.8 M) | (341.4 M) | (281.9 M) | (253.7 M) | (241 M) |
| RYTM | (18.1 M) | (18.1 M) | (18.1 M) | (21.4 M) | (6.5 M) | (11.1 M) | (25.9 M) | (33.7 M) | (74.1 M) | (134.6 M) | (130.7 M) | (68 M) | (181.1 M) | (184.7 M) | (260.6 M) | (234.5 M) | (222.8 M) |
| ABVX | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.1 M) | (16 M) | (14.3 M) | (11.2 M) | (15.8 M) | (30.6 M) | (37.6 M) | (42.5 M) | (60.7 M) | (147.7 M) | (176.2 M) | (158.6 M) | (150.7 M) |
| TECH | 400 K | 112.3 M | 112.6 M | 110.9 M | 107.7 M | 104.5 M | 77.3 M | 125.3 M | 96.1 M | 229.3 M | 140.4 M | 272.1 M | 285.3 M | 168.1 M | 73.4 M | 84.4 M | 87.1 M |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 599.5 M | 629.4 M |
| BMRN | (12.3 M) | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 854 M | (64.1 M) | 141.6 M | 167.6 M | 426.9 M | 26.8 M | 28.1 M |
| BAX | 137 M | 2.2 B | 2.3 B | 2 B | 2.5 B | 968 M | 5 B | 602 M | 1.5 B | 1 B | 1.1 B | 1.3 B | (2.4 B) | 2.7 B | (649 M) | (746.4 M) | (709 M) |
Madrigal Pharmaceuticals and related stocks such as Avidity Biosciences, Jazz Pharmaceuticals PLC, and Moderna Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Madrigal Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Madrigal Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Madrigal Pharmaceuticals Competitive Analysis
The better you understand Madrigal Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Madrigal Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Madrigal Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Madrigal Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Madrigal Pharmaceuticals Competition
Madrigal Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Madrigal Pharmaceuticals in relation to its competition. Madrigal Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Madrigal Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Madrigal Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Madrigal Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Madrigal Pharmaceuticals position
In addition to having Madrigal Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Adviser Favorites Thematic Idea Now
Adviser Favorites
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Madrigal Pharmaceuticals Correlation with its peers. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.91) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.